Filtros de búsqueda

Lista de obras de Javier Cortes

"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy

artículo científico publicado en 2015

18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial.

artículo científico publicado en 2016

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM).

artículo científico publicado en 2016

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies

artículo científico publicado en 2015

A mouse model uncovers LKB1 as an UVB-induced DNA damage sensor mediating CDKN1A (p21WAF1/CIP1) degradation

artículo científico publicado en 2014

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

artículo científico publicado en 2014

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

artículo científico publicado en 2017

A roadmap for accelerated drug approval in breast cancer?

scientific article published on 09 August 2012

ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment

artículo científico publicado en 2017

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

scientific article published on 20 September 2020

Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel

artículo científico publicado en 2013

Acute lung injury associated with docetaxel and bevacizumab.

artículo científico publicado en 2007

Adjuvant bevacizumab: positive data from a negative trial

artículo científico publicado en 2013

Advances in first-line treatment for patients with HER-2+ metastatic breast cancer

artículo científico publicado en 2012

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis

artículo científico publicado en 2011

Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis

artículo científico publicado en 2020

Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens.

artículo científico publicado en 2013

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, rando

artículo científico publicado en 2014

Beyond taxanes: the next generation of microtubule-targeting agents

artículo científico publicado en 2012

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

artículo científico publicado en 2014

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

artículo científico publicado en 2013

Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?

artículo científico publicado en 2012

Breast-Conservative Surgery Followed by Radiofrequency Ablation of Margins Decreases the Need for a Second Surgical Procedure for Close or Positive Margins

scientific article published on 21 February 2014

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

artículo científico publicado en 2017

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

artículo científico

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

artículo científico publicado en 2013

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

artículo científico publicado en 2015

Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases

artículo científico publicado en 2016

Changes in breast cancer reports after pathology second opinion.

artículo científico

Circulating tumour cells in early breast cancer

Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis

artículo científico publicado en 2021

Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

artículo científico publicado en 2002

Complete Pathological Remission in a Patient with Hormone-Receptor Positive and c-erbB-2 Expression-Negative Breast Cancer Treated with FAC Chemotherapy during Pregnancy ⬇️

artículo científico publicado el 1 de julio de 2010

Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2.

artículo científico publicado en 2013

Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain ⬇️

artículo científico publicado el 1 de octubre de 2010

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients

artículo científico publicado en 2011

Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.

artículo científico publicado en 2013

Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.

artículo científico publicado en 2016

Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?

artículo científico publicado en 2012

Docetaxel combined with targeted therapies in metastatic breast cancer

artículo científico

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer

artículo científico publicado en 2012

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

artículo científico publicado en 2015

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer

artículo científico publicado en 2016

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

artículo científico publicado en 2014

Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts.

artículo científico publicado en 2016

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

artículo científico publicado en 2014

Enhancing global access to cancer medicines

artículo científico publicado en 2020

Epidermal growth factor receptor pathway inhibitors.

artículo científico publicado en 2005

Eribulin Mesylate: A Promising New Antineoplastic Agent for Locally Advanced or Metastatic Breast Cancer ⬇️

artículo científico publicado el 7 de marzo de 2011

Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer

artículo científico publicado en 2011

Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

artículo científico publicado en 2014

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

artículo científico publicado en 2011

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized con

artículo científico publicado en 2016

Erratum to: Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

artículo científico publicado en 2015

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing

artículo científico publicado en 2013

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

artículo científico publicado en 2015

Etirinotecan pegol for the treatment of breast cancer

artículo científico publicado en 2016

Expert perspectives on biosimilar monoclonal antibodies in breast cancer

artículo científico publicado en 2014

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

artículo científico publicado en 2007

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

artículo científico publicado en 2016

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

artículo científico publicado en 2013

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

artículo científico publicado en 2012

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.

artículo científico publicado en 2003

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

scientific article published on 22 July 2016

Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).

artículo científico publicado en 2009

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast

artículo científico publicado en 2015

Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations.

artículo científico publicado en 2016

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

artículo científico publicado en 2014

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity

artículo científico publicado en 2013

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.

artículo científico publicado en 2014

HER2 and hormone receptor-positive breast cancer--blocking the right target

artículo científico publicado en 2010

HER2 testing: current status and future directions.

artículo científico

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

artículo científico publicado en 2017

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

artículo científico publicado en 2016

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial ⬇️

artículo científico publicado en 2015

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial ⬇️

artículo científico publicado en 2017

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

artículo científico publicado en 2013

Hepatic Resection for Liver Metastases as Part of the “Oncosurgical” Treatment of Metastatic Breast Cancer

artículo científico publicado en 2008

High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.

artículo científico publicado en 2014

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

artículo científico publicado en 2015

How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer

artículo científico publicado en 2009

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis

artículo científico publicado en 2012

In response: Genomic profile of breast cancer

artículo científico publicado en 2015

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab

artículo científico

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA.

artículo científico publicado en 2014

Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

artículo científico publicado en 2021

Influencing cancer treatment

artículo científico publicado en 2015

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated

artículo científico publicado en 2009

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

artículo científico publicado en 2017

Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study

artículo científico publicado en 2002

Is the Proportion of Patients Diagnosed with Synchronous Stage IV Breast Cancer Who Survive More than Two Years Increasing over Time?

artículo científico publicado en 2015

Javier Cortés, MD, on the CLEOPATRA Trial

artículo científico publicado en 2015

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas

artículo científico publicado en 2013

Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study

scientific article published on 16 October 2019

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

artículo científico publicado en 2017

Management of the axilla in early breast cancer patients in the genomic era.

artículo científico publicado en 2012

Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth

artículo científico publicado en 2010

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients

artículo científico publicado en 2015

Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer

artículo científico publicado en 2014

Molecular pathways: targeting hsp90--who benefits and who does not.

artículo científico

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.

artículo científico publicado en 2012

Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes

artículo científico publicado en 2012

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.

artículo científico

Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation.

artículo científico publicado en 2015

New approach to cancer therapy based on a molecularly defined cancer classification.

artículo científico publicado en 2013

New approaches in angiogenic targeting for colorectal cancer.

artículo científico publicado en 2007

Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study

artículo científico publicado en 2009

Nontaxane microtubule dynamics inhibitors

artículo científico publicado el 1 de marzo de 2011

Novel treatment options in the management of metastatic breast cancer.

scientific article published on May 2011

Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma

artículo científico publicado en 2011

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

scientific article published on 22 August 2012

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer

artículo científico publicado en 2015

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients

artículo científico publicado en 2019

Paclitaxel, cisplatin, and vinorelbine combination chemotherapy in metastatic non-small-cell lung cancer.

artículo científico publicado en 2004

Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

scientific article published on 16 September 2020

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies

artículo científico publicado en 2015

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

artículo científico publicado en 2012

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

artículo científico publicado en 2013

Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer

scientific article published on 30 September 2020

Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.

artículo científico publicado en 2016

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors

artículo científico publicado en 2012

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

scientific article published on 02 August 2010

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy

artículo científico publicado en 2017

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

artículo científico publicado en 2015

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane ⬇️

artículo científico publicado en 2015

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

artículo científico publicado en 2010

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

artículo científico publicado en 2014

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

artículo científico publicado en 2010

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

artículo científico publicado en 2014

Potential clinical applications of halichondrins in breast cancer and other neoplasms.

artículo científico publicado en 2012

Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis.

artículo científico publicado en 2011

Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer

artículo científico publicado en 2005

Prognostic and predictive factors and genetic analysis of early breast cancer.

artículo científico publicado en 2009

Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation

artículo científico publicado en 2006

Progress against solid tumors in danger: the metastatic breast cancer example

artículo científico publicado en 2012

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

artículo científico publicado en 2019

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

artículo científico publicado en 2015

Re: Time to Adjuvant Chemotherapy for Breast Cancer in National Comprehensive Cancer Network Institutions

artículo científico publicado en 2013

Recognizing the place of trials with treatment of physician's choice as the control arm.

artículo científico publicado en 2015

Reply to A. Ocana et al.

artículo científico publicado en 2013

Research needs in breast cancer.

artículo científico publicado en 2016

Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients

artículo científico publicado en 2009

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

artículo científico publicado en 2017

Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence?

artículo científico publicado en 2005

Réponse de D. Torrejon, J. Cortes, D. Serpico, S. Di Cosimo à l’article de F. Vasseur et al. : KI67 chez les patientes jeunes présentant un cancer du sein. Gynecol Obstet Fertil 2013; 41(1):16-9

scientific article published on 04 June 2013

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

artículo científico publicado en 2014

Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial ⬇️

artículo científico publicado en 2016

Safety of bevacizumab in metastatic breast cancer patients undergoing surgery.

artículo científico publicado en 2011

Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat?

artículo científico

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer ⬇️

artículo científico publicado en 2016

Survival of women with inflammatory breast cancer: a large population-based study

artículo científico publicado en 2014

Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts

artículo científico

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group

artículo científico publicado en 2017

The beautiful history of pertuzumab.

artículo científico publicado en 2012

The effect of biology in the treatment of small breast tumors

artículo científico publicado en 2013

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer

artículo científico publicado en 2015

The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.

artículo científico publicado en 2014

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

artículo científico publicado en 2021

The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy

artículo científico publicado en 2011

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors

scientific article published on 09 August 2011

mTOR inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions.

artículo científico publicado en 2012

p95HER2-T cell bispecific antibody for breast cancer treatment

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda